These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37479967)

  • 1. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
    Chitrangi S; Vaity P; Jamdar A; Bhatt S
    BMC Cancer; 2023 Jul; 23(1):689. PubMed ID: 37479967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
    de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
    Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.
    Chan WS; Mo X; Ip PPC; Tse KY
    Cancer Med; 2023 Oct; 12(19):19714-19731. PubMed ID: 37776168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
    Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
    Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
    Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
    Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
    J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
    Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
    Thorel L; Morice PM; Paysant H; Florent R; Babin G; Thomine C; Perréard M; Abeilard E; Giffard F; Brotin E; Denoyelle C; Villenet C; Sebda S; Briand M; Joly F; Dolivet E; Goux D; Blanc-Fournier C; Jeanne C; Villedieu M; Meryet-Figuiere M; Figeac M; Poulain L; Weiswald LB
    J Exp Clin Cancer Res; 2023 Oct; 42(1):260. PubMed ID: 37803448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
    Chen P; Zhang X; Ding R; Yang L; Lyu X; Zeng J; Lei JH; Wang L; Bi J; Shao N; Shu D; Wu B; Wu J; Yang Z; Wang H; Wang B; Xiong K; Lu Y; Fu S; Choi TK; Lon NW; Zhang A; Tang D; Quan Y; Meng Y; Miao K; Sun H; Zhao M; Bao J; Zhang L; Xu X; Shi Y; Lin Y; Deng C
    Adv Sci (Weinh); 2021 Nov; 8(22):e2101176. PubMed ID: 34605222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
    Thorel L; Divoux J; Lequesne J; Babin G; Morice PM; Florent R; Desmartin G; Lecouflet L; Marde Alagama C; Leconte A; Clarisse B; Briand M; Rouzier R; Gaichies L; Martin-Françoise S; Le Brun JF; Denoyelle C; Vigneron N; Jeanne C; Blanc-Fournier C; Leman R; Vaur D; Figeac M; Meryet-Figuiere M; Joly F; Weiswald LB; Poulain L; Dolivet E
    BMC Cancer; 2024 Jun; 24(1):701. PubMed ID: 38849726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
    Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
    J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients.
    Choi W; Kim YH; Woo SM; Yu Y; Lee MR; Lee WJ; Chun JW; Sim SH; Chae H; Shim H; Lee KS; Kong SY
    Cancer Res Treat; 2023 Oct; 55(4):1077-1086. PubMed ID: 37309112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
    Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
    Kumar S; Raina M; Tankay K; Ingle GM
    Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    Tao M; Wu X
    J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
    Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
    J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-derived Organoids.
    Ding L; Yang Y; Lu Q; Cao Z; Weygant N
    Curr Cancer Drug Targets; 2022; 22(3):195-208. PubMed ID: 35078398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.